Pulxion Medical Technology, founded by Professor Hao-Ming Hsiao (NTU Engineering) and Dr. Hsien-Li Kao (NTUH Cardiology), is tackling one of healthcare’s silent threats: stroke caused by undetected carotid artery stenosis.

Now under the leadership of CEO Joy Chen—an industry veteran with 20+ years in biotech and pharma—Pulxion is launching PulStroke®, a rapid, standardized, and cost-efficient AI-based carotid screening tool. With just 1 minute for imaging and 5 minutes for risk reporting, it addresses the urgent need for scalable early detection.

The company has already secured two patents in Taiwan and the U.S., and is planning clinical trials this year. Regulatory approvals are targeted for Taiwan in 2025 and the U.S. in 2026. Pulxion is also building a robust go-to-market strategy, including corporate wellness, public health programs, and B2B medical partnerships.

Stroke doesn’t happen overnight. But with visionary leadership and clinical rigor, prevention can.

Read more: http://bit.ly/v118company

Follow Globalbio for more updates on Medtech!